Angle (AGL)


AGL Share PerformanceMore

52 week high80.00 15/06/17
52 week low32.27 07/09/17
52 week change -30.50 (-45.86%)
4 week volume5,432,564 30/08/17

Media for (AGL)

Presenter: Andrew Newland, Chief Executive

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 6884Q Angle PLC 13 September 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: ANGLE plc 1b. Please in...

Exclusive worldwide option over megakaryocyte IP

RNS Number: 5663Q Angle PLC 13 September 2017 For immediate release 13 September 2017 ANGLE plc ("the Company") EXCLUSIVE WORLDWIDE OPTION OVER MEGAKARYOCYTE INTELLECTUAL PROPERTY ANGLE signs option over patent applications filed on Barts Cancer Institute's discovery of megakaryocytes' role in cancer Megakaryocytes' pre...

Co-Marketing Partnership with QIAGEN

RNS Number: 2994Q Angle PLC 11 September 2017 For immediate release 11 September 2017 ANGLE plc ("the Company") ANGLE ANNOUNCES CO-MARKETING PARTNERSHIP WITH QIAGEN Combines ANGLE's CTC harvesting technology with QIAGEN's downstream analysis and bioinformatics capabilities for circulating tumor cell research ANGLE plc...

Broker Forecast - finnCap issues a broker note on Angle PLC

finnCap today initiates coverage of Angle PLC (LON:AGL) with a corporate investment rating and price target of 100p.

ANGLE appoints Nomad

ANGLE has appointed finnCap Ltd as the company's nominated adviser and joint broker with immediate effect. WG Par...

Change of Adviser

RNS Number: 7872P Angle PLC 05 September 2017 5 September 2017 ANGLE plc ("the Company") Change of Adviser ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointment of finnCap Ltd as Nominated Adviser and Joint Broker with immediate effect. WG Partners remains Joint Broker to the Co...

ANGLE welcomes new research on Parsortix

ANGLE said new research by Heinrich Heine University of Duesseldorf demonstrated the the measurement of key protei...

New Research with Parsortix

RNS Number: 6637P Angle PLC 04 September 2017 For immediate release 4 September 2017 ANGLE plc ("the Company") NEW RESEARCH WITH PARSORTIX DEMONSTRATES ABILITY TO IDENTIFY KEY PROTEINS INVOLVED IN BREAST CANCER CELL GROWTH AND SURVIVAL Parsortix harvests relevant cells missed by antibody-based system...

Fundamental DataMore

Dividend yield0 %

Equity Research (AGL)

edison investment research
This morning Angle reported initial results from its two lead clinical trials with Parsortix, a liquid biopsy system. The two studies ran in parallel in Europe (ANG-001) and the US (ANG-003) and...
edison investment research
Yesterday Angle announced that researchers from Queen Mary University of London's Barts Cancer Institute (BCI) published new data further supporting Angle’s Parsortix system for use in prostate...
Toople* (TOOP.L) 3.25p £3.25m The provider of bespoke telecom services to UK SMEs, announced that it received a strong response from investors pursuant to Initial C l o s i n g o f t h e...

Latest discussion posts More

  • Re: Lombard

    Looking at the quantity they have reduced, I would think that is a change in policy. Given the limited change in SP, I would expect that there will be a balancing movement by ...
    claude reins
  • Lombard

    If i am reading correctly Lombard have significantly reduced their holding. I would have thought it's worth an increase at these prices and have topped up. What do they know ...
    Good money after bad
  • Re: Qiagen

    This is more like it. It was the natural way to go. Qiagen, with 500k contacts, 4500 employees around the world, a lot of associated techniques into which Angle's programme ...
    claude reins

Users' HoldingsMore

Users who hold Angle also hold..
RDS 'B'14%

Codes & Symbols